|
|
Post by BD on Apr 10, 2014 11:35:02 GMT -5
12:29 EDT MNKD theflyonthewall.com: MannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70. :theflyonthewall.com
|
|
|
|
Post by liane on Apr 10, 2014 11:45:57 GMT -5
I don't think this has anything to do with DNCE. The whole IBB is in a slump again. DNCe's product is totally unlike Afrezza. It is aerolsolized. Still no major studies, and years away from an NDA. I believe too that the PK is nothing special.
|
|
|
|
Post by BD on Apr 10, 2014 11:48:53 GMT -5
OK, so basically I'll file this away as another attempt at a smoke-screen to cover shorting/manipulation efforts. Business as usual, lol.
|
|
|
|
Post by mannmade on Apr 10, 2014 12:03:34 GMT -5
Here is my immediate and initial response to a friend who sent me the same article earlier and asked my opinion:
Appreciate it. Had not seen this yet. Will forward to my email group.
My thoughts are as follows knowing only what I read in the article at the link below:
1.) they are at least 3 years behind Mannkind in going to market
2.) cough is not really a big deal for most
3.) mnkd’s Afrezza is a new first in class ultra rapid acting insulin which is the real reason diabetics should switch to eliminate Hypo events. And btw, exhubera was not and this one is also likely not. And btw, mnkd holds the patent rights until 2031
4.) mnkd’s real value may be beyond Afrezza with technosphere platform and pain killer product development
5.) Balance sheet is not a concern. They also have 10B in retail inventory based on raw insulin they have in storage plus carry forward tax losses of 2B that should be attractive for a partner and which will keep first 2 to 3 years of COG very low.
6.) Device looks much bulkier/bigger. Can hide Gen 2 in your shirt pocket
7.) It appears at very least the device needs batteries and is not disposable like Gen 2 which means more expensive (electronic internals) and not as advantageous for third world nor as inexpensive as Afrezza which may make tough to get insurance coverage
8.) Afrezza does not need to be refrigerated and liquid insulin does
9.) There are several current prandial insulins on the market and the two market leaders are both multi billion dollar drugs so if it is eventually proven to be capable option then by all means
10.) Much less risk with Afrezza as an investor
Just my immediate and initial thoughts…
Thanks,
|
|
|
|
Post by mannmade on Apr 10, 2014 12:03:56 GMT -5
My pst appeared twice so deleted this one
|
|
|
|
Post by babaoriley on Apr 10, 2014 12:32:42 GMT -5
OK, so basically I'll file this away as another attempt at a smoke-screen to cover shorting/manipulation efforts. Business as usual, lol. Absolutely, that's ridiculous it's so far behind. So you think you can Dance? I don't think so! |
|
|
|
Post by spiro on Apr 10, 2014 13:02:38 GMT -5
it looks like they have only done a phase 1/11 with only 12 patients? MNKD will be selling Technosphere pain medication by the time that device gets approval. Baba, two men wearing Fedoras and black suits will be coming to have a little chat with you soon.
|
|
|
|
Post by jpg on Apr 13, 2014 11:28:42 GMT -5
I personally hope their IPO goes very well. Having another player in the game will only benefit us. Especially one with a product which seems different (inferior?) to ours.
|
|
|
|
Post by ezrasfund on Apr 13, 2014 11:51:22 GMT -5
Actually I think it is Dance that is trying to take a ride on the coattails of Afrezza. After all if Afrezza is not approved these guys are dead in the water. They are anyway. But like Afrezza vs Exubera, these guys are twice dead if Afrezza does not succeed.
|
|
|
|
Post by jpg on Apr 13, 2014 11:55:40 GMT -5
Actually I think it is Dance that is trying to take a ride on the coattails of Afrezza. After all if Afrezza is not approved these guys are dead in the water. They are anyway. But like Afrezza vs Exubera, these guys are twice dead if Afrezza does not succeed. Agreed. Imitation is the highest form of flattery... |
|
